(R)-2-氯-3-(2-甲基哌嗪-1-基)吡嗪 | 313657-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (R)-2-氯-3-(2-甲基哌嗪-1-基)吡嗪
• 中文别名: 2-氯-3-((R)-2-甲基-1-吡嗪基)吡嗪
• 英文名称: (R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine
• 英文别名: (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine；(R)-2-Chloro-3-(2-methylpiperazin-1-YL)pyrazine；2-chloro-3-[(2R)-2-methylpiperazin-1-yl]pyrazine
• CAS: 313657-76-0
• 化学式: C₉H₁₃ClN₄
• 分子量: 212.682
• InChiKey: OGTLIDNRGOUIAQ-SSDOTTSWSA-N

物化性质

• 沸点：
  344.6±42.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  41
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-氯-3-(2-甲基哌嗪-1-基)吡嗪 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 反应 1.0h， 生成 (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine, fumarate
  参考文献：
  名称：

  [EN] NOVEL PROCESS
  [FR] NOUVEAU PROCEDE

  摘要：

  本发明涉及一种用于制备在中枢神经系统中具有治疗活性的化合物的过程。在一个方面，本发明涉及一种制备通式（I）化合物的过程。本发明还涉及（2R）-1-（3-氯-2-吡啶基）-2-甲基哌嗪盐酸盐及其制备方法。本发明的另一个目的是一种通式（I）化合物。本发明的另一个目的是一种用于治疗或预防与5-羟色胺相关的疾病的方法，包括向需要的受试者施用上述化合物的有效量；以及利用该化合物制造用于治疗5-羟色胺相关疾病的药物。

  公开号：

  WO2004000829A1
• 作为产物：
  描述：

  2-甲基哌嗪 在 sodium hydroxide 、 硫酸 、 potassium carbonate 、 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 branched octane 、 乙醇 、 二氯甲烷 、 水 、 异丙醇 、 乙腈 为溶剂， 反应 47.5h， 生成 (R)-2-氯-3-(2-甲基哌嗪-1-基)吡嗪
  参考文献：
  名称：

  [EN] NOVEL PROCESS
  [FR] NOUVEAU PROCEDE

  摘要：

  本发明涉及一种用于制备在中枢神经系统中具有治疗活性的化合物的过程。在一个方面，本发明涉及一种制备通式（I）化合物的过程。本发明还涉及（2R）-1-（3-氯-2-吡啶基）-2-甲基哌嗪盐酸盐及其制备方法。本发明的另一个目的是一种通式（I）化合物。本发明的另一个目的是一种用于治疗或预防与5-羟色胺相关的疾病的方法，包括向需要的受试者施用上述化合物的有效量；以及利用该化合物制造用于治疗5-羟色胺相关疾病的药物。

  公开号：

  WO2004000829A1

文献信息

• Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
  申请人：Biovitrum AB

  公开号：US06465467B1

  公开（公告）日：2002-10-15

  Compounds of the general formula (I): wherein the variables are as defined in the specification are useful for the prophylaxis or treatment of serotonin-related, especially 5-HT2 receptor-related, diseases in human beings or animals, particularly diseases related to the 5-HT2c receptor, especially diseases such as eating disorders, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctionions, and urinary disorders.

  通式（I）的化合物： 其中变量如规范中定义的那样，对于预防或治疗人类或动物中与血清素相关，特别是5-HT2受体相关的疾病是有用的，特别是与5-HT2c受体相关的疾病，尤其是与进食障碍、记忆障碍、精神分裂症、情绪障碍、焦虑障碍、疼痛、性功能障碍和尿液障碍等疾病相关的疾病。
• Synthesis of PNU-243922 labelled with¹⁴C
  作者：C. Felicini、E. Fontana、D. Giribone、B. M. Nilsson、K. Österlund、A. Paptchikhine

  DOI：10.1002/jlcr.646

  日期：2003.1

  The arylpiperazine PNU-243922 (1) has been labelled with 14C. A two-step sequence starting from the 14C labelled alcohol 6a led to radiochemically pure (>98%) [14C]PNU-243922 with a specific activity of 546 MBq/mmol Copyright © 2002 John Wiley & Sons, Ltd.

  芳基哌嗪 PNU-243922 (1) 已用 14C 标记。从 14C 标记的醇 6a 开始，经过两个步骤，得到了放射化学纯（>98%）的 [14C]PNU-243922，其比活度为 546 MBq/mmol Copyright © 2002 John Wiley & Sons, Ltd. All Rights Reserved.
• CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES
  申请人：Biovitrum, AB, a Stockholm, Sweden corporation

  公开号：US20040242554A1

  公开（公告）日：2004-12-02

  The invention relates to compounds of the general formula (I): 1 wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO 2 —, —NH—, (ii) a C 1-4 -alkyl- or C 1-6 -acyl-substituted nitrogen atom or (iii) a C 1-8 -alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R 4 )(R 5 )—, —OC(R 4 )(R 5 )—, —N(R 6 )C(R 4 )(R 5 )—, —N(R 6 )—, —O—, —S— or —SO 2 —; R is optionally substituted C 3-8 -cycloalkyl, aryl or heteroaryl; R 1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R 4 )(R 5 )] x N(R 2a )(R 3a )]; R 2a , R 3a , R 4 , R 5 , R 6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory, disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).

  本发明涉及通式（I）的化合物：其中Ar是可选取代的芳基或杂芳基；A是（i）—O—，—S—，—SO2—，—NH—，（ii）C1-4烷基或C1-6酰基取代的氮原子，或（iii）C1-8烷基链或具有2-8链原子的杂烷基链，其可选包含至少一个不饱和度，并且可以取代和/或含有桥接以形成具有3-8环成员的饱和或部分或完全不饱和环；B是—C（R4）（R5）—，—OC（R4）（R5）—，—N（R6）C（R4）（R5）—，—N（R6）—，—O—，—S—或—SO2—；R是可选取代的C3-8环烷基，芳基或杂芳基；R1是（i）饱和或不饱和的氮杂环或氨基氮杂环，或饱和的二氮杂环或氨基二氮杂环，其具有4-7环成员，或饱和的氨基氮杂双环、氮杂双环或二氮杂双环，其具有7-10环成员，这些环在一个或多个位置上可选取代，或者是一个组—[C（R4）（R5）]xN（R2a）（R3a）；R2a，R3a，R4，R5，R6和x如权利要求中所定义，n为0或1；以及其药学上可接受的盐、水合物和前药形式。这些化合物可以通过常规方法制备，并可用于治疗患有血清素相关疾病的人或动物，例如进食障碍，尤其是肥胖症，记忆障碍，精神分裂症，情绪障碍，焦虑障碍，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含通式（I）化合物的制药组合物。
• Novel process
  申请人：Fleck Tom

  公开号：US20060142578A1

  公开（公告）日：2006-06-29

  The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. (I)n one aspect, the invention relates to a process for the preparation of compounds of the general formula ((I)): wherein HA is a pharmaceutically acceptable acid and R 1 -R 4 are each independently selected from the group consisting of hydrogen, halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, and di-C 1 -C 6 -alkylamino-C 2 -C 6 -alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.

  本发明涉及一种制备在中枢神经系统中具有治疗活性的化合物的方法。(在一方面，本发明涉及一种制备具有通式(I)的化合物的方法：其中HA是一种药学上可接受的酸，R1-R4分别独立地选自氢、卤素、C1-C6烷基、C1-C6烷氧基和二C1-C6烷基氨基-C2-C6烷氧基的群。本发明还涉及使用该化合物制造治疗血清素相关疾病的药物。
• Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
  申请人：Biovitrum, AB, a Stockholm, Sweden corporation

  公开号：US20030092694A1

  公开（公告）日：2003-05-15

  The invention relates to compounds of the general formula (I): 1 wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO 2 —, —NH—, (ii) a C 1-4 -alkyl- or C 1-6 -acyl-substituted nitrogen atom or (iii) a C 1-8 -alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R 4 )(R 5 )—, —OC(R 4 )(R 5 )—, —N(R 6 )C(R 4 )(R 5 )—, —N(R 6 )—, —O—, —S— or —SO 2 —; R is optionally substituted C 3-8 -cycloalkyl, aryl or heteroaryl; R 1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R 4 )(R 5 )] x N(R 2a )(R 3a )]; R 2a , R 3a , R 4 , R 5 , R 6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I)

  本发明涉及一般式（I）的化合物：其中Ar是可选取代的芳基或杂环芳基；A是（i）-O-，-S-，-SO2-，-NH-，（ii）C1-4-烷基或C1-6-酰基取代的氮原子或（iii）C1-8-烷基链或具有2至8个链原子的杂烷基链，可选地含有至少一个不饱和度，并且可以取代和/或包含桥以形成具有3-8个环成员的饱和或部分或完全不饱和的环；B是-C（R4）（R5）-，-OC（R4）（R5）-，-N（R6）C（R4）（R5）-，-N（R6）-，-O-，-S-或-SO2-；R是可选取代的C3-8-环烷基，芳基或杂环芳基；R1是（i）饱和或不饱和的氮杂环或氨基氮杂环环，或具有4至7个环成员的饱和二氮杂环或氨基二氮杂环环，或具有7至10个环成员的饱和氨基氮杂双环、氮杂双环或二氮杂双环环，这些环可选地在一个或多个位置上取代，或一个组-［C（R4）（R5）］xN（R2a）（R3a）；其中R2a，R3a，R4，R5，R6和x如所述，n为0或1；以及其药学上可接受的盐、水合物和前药形式。这些化合物可以通过常规方法制备，并可用于治疗患有血清素相关疾病的人类或动物受试者，例如进食障碍，特别是肥胖，记忆障碍，精神分裂症，情绪障碍，焦虑症，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含式（I）化合物的药物组合物。